Generic Name: tralokinumab
Brand Name: TBC
Manufacturer: LEO Pharma Inc.
Therapeutic Area: atopic dermatitis
Indications: Tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. TRADENAME (tralokinumab) can be used with or without topical corticosteroids.
Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and who had an adequate trial or be ineligible for each of the following therapies: phototherapy (where available), methotrexate, and cyclosporine.
Submission Type: Initial
Project Status: Pending
Call for patient/clinician input open: March 30, 2021
Call for patient/clinician input closed: May 21, 2021
Anticipated Date: April 28, 2021
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.